Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
AntiRadical Therapeutics LLC
Bayer AG
Boehringer Ingelheim Intertiol GmbH
Cyclerion Therapeutics Inc
Gurus BioPharm Inc
Innovative Pharmacology Research
Merck & Co Inc
NicOx SA
Nitric Oxide Innovations LLC
Novartis AG
Novoteris LLC
Toa Eiyo Ltd
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
A-8R - Drug Profile
Product Description
Mechanism Of Action
BAY-1211163 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BAY-1237592 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BAY-3283142 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BAY-546544 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-685509 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CY-3018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CY-6463 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GRS - Drug Profile
Product Description
Mechanism Of Action
GUR-501 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GUR-602 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-5475 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mosliciguat - Drug Profile
Product Description
Mechanism Of Action
proxcinod - Drug Profile
Product Description
Mechanism Of Action
History of Events
NCX-470 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NCX-667 SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
nitric oxide - Drug Profile
Product Description
Mechanism Of Action
History of Events
nitric oxide - Drug Profile
Product Description
Mechanism Of Action
History of Events
olinciguat - Drug Profile
Product Description
Mechanism Of Action
History of Events
praliciguat - Drug Profile
Product Description
Mechanism Of Action
History of Events
riociguat - Drug Profile
Product Description
Mechanism Of Action
History of Events
runcaciguat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate sGC for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile
Product Description
Mechanism Of Action
TOPN-53 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TOPT-5 - Drug Profile
Product Description
Mechanism Of Action
TOPV-122 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TY-55002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vacno - Drug Profile
Product Description
Mechanism Of Action
History of Events
vericiguat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
Featured News & Press Releases
Oct 06, 2022: Cyclerion announces mitochondrial disease-focused corporate strategy
Sep 29, 2022: Bayer launches vericiguat (Verquvo) in India, the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalizations
Sep 19, 2022: Nicox announces last patients complete fil visit in NCX 470 phase 3 Mont Blanc glaucoma trial
Jul 28, 2022: Cyclerion Therapeutics announces positive topline clinical data for CY6463 in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Jul 07, 2022: Nicox announces publication of NCX 470 results demonstrating improvements to ocular hemodymics and retil cell physiology
Jun 28, 2022: Cyclerion Therapeutics provides additiol positive CY6463 MELAS clinical data at a webi hosted by United Mitochondrial Disease Foundation
Jun 22, 2022: Cyclerion Therapeutics to discuss CY6463 MELAS Clinical Data at a Webir Hosted by United Mitochondrial Disease Foundation
Jun 17, 2022: Cyclerion Therapeutics announces CY6463 data demonstrating improved cellular energetics in preclinical models of mitochondrial disease
Jun 10, 2022: Cyclerion Therapeutics announces positive topline clinical data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Jun 06, 2022: Cyclerion Therapeutics to share CY6463 MELAS topline study results, CHOP to present CY6463 preclinical data at UMDF Mitochondrial Medicine 2022 Symposium
Jun 03, 2022: Nicox accelerates topline results from NCX 470 Mont Blanc phase 3 glaucoma trial to November 2022
May 19, 2022: Verquvo (vericiguat) approved in Chi to treat patients with chronic heart failure and reduced ejection fraction
May 17, 2022: New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore
May 04, 2022: Cyclerion announces CY6463 clinical pipeline progress
May 02, 2022: Nicox at ARVO 2022: Presentation of new non-clinical evidence of improved hemodymic and retil cell physiology on NCX 470
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Akebia Therapeutics Inc, 2022
Pipeline by AntiRadical Therapeutics LLC, 2022
Pipeline by Bayer AG, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Cyclerion Therapeutics Inc, 2022
Pipeline by Gurus BioPharm Inc, 2022
Pipeline by Innovative Pharmacology Research, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by NicOx SA, 2022
Pipeline by Nitric Oxide Innovations LLC, 2022
Pipeline by Novartis AG, 2022
Pipeline by Novoteris LLC, 2022
Pipeline by Toa Eiyo Ltd, 2022
Pipeline by Topadur Pharma AG, 2022
Dormant Products, 2022
Discontinued Products, 2022